Abstract: The present invention relates to a synthetic promoter operably linked to a daptomycin biosynthetic gene cluster; a gene construct for producing daptomycin in which the synthetic promoter and a daptomycin biosynthetic gene cluster are operably linked; a recombinant expression vector for producing daptomycin containing the genetic construct; and a transformant for producing daptomycin that has been transformed with the recombinant expression vector, wherein the synthetic promoter can increase the transcriptional activity of the daptomycin biosynthetic gene cluster, and the transformant that has been transformed with the recombinant expression vector containing the synthetic promoter and the daptomycin biosynthetic gene cluster can be effectively used in the field of medicine and pharmacy by enabling mass production of daptomycin.

Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2-R5 and R10-R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.

Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2-R5 and R10-R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.

Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2—R5 and R10—R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.

Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2—R5 and R10—R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.

Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2-R5 and R10-R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.